March 13, 2025 · Form 4 insider transaction
Anzalone Christopher Richard bought 340,000 shares of Arrowhead Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Represents performance awards granted on December 22, 2023, and certified on March 12, 2025, upon the achievement of certain performance goals.